Neurology Diagnostics’ Role in Advancing Alzheimer’s Research: LUCIDITY Phase 3 Outcomes
We are pleased to announce advancements in Alzheimer’s Disease research, stemming from the Phase 3 LUCIDITY trial!
Dr. Joel Vandersluis, has been selected as a 2023 Health Care Hero.
We are thrilled to announce that our very own Dr. Joel Vandersluis has been selected as a 2023 Health Care Hero! This prestigious recognition celebrates those who have made significant contributions to health care through their concern for patients, their research and inventions, their management skills, their innovative programs for employees, and their service to the poor and uninsured.
As the primary neurologist at Neurology Diagnostics in Dayton, Ohio, Dr. Vandersluis has shown exceptional concern for his patients, tirelessly working to improve their health outcomes and quality of life. His dedication to research and innovation has resulted in groundbreaking programs and inventions that have advanced health care delivery and management.
We'd also like to extend our congratulations to all the other winners of the 2023 Health Care Heroes award. Your hard work and dedication to improving health care for patients is truly inspiring.
We're proud to have Dr. Vandersluis on our team, and we're honored to see him recognized as a 2023 Health Care Hero. Congratulations, Dr. Vandersluis!
Stay up to date with the latest news and updates from Neurology Diagnostics by visiting our website or following us on social media.
Learn more here: https://www.bizjournals.com/dayton/event/169109/2023/2023-health-care-heroes
You Might Also Enjoy...
FDA Approves Leqembi, Expanding Alzheimer's Treatment, with Contributions from Neurology Diagnostics
We are thrilled to share that the FDA has granted approval for Leqembi, a groundbreaking drug that offers new hope for Alzheimer's patients. Leqembi is an antibody that targets amyloid in the brain, in order to slow the progress of Alzheimer’s.
Neurology Diagnostics (NDx) Contributes to Lilly's Alzheimer's Clinical Trial Success
Neurology Diagnostics (NDx) is proud to have been selected for Lilly's ALZ 2 Trailblazer trial and has been seeing patients in this trial since July 2020. As part of the study, NDx has randomized 39 patients of the trial's >1700 patients
New Test Offers Early Parkinson's Disease Detection: A Promising Step Forward in Parkinson's Awarene
A new study in The Lancet Neurology has brought hope to both researchers and patients, as it presents a novel way to test for Parkinson's disease even before any symptoms show up.
Parkinson's Disease Clinical Trial
Parkinson's disease afflicts over one million people in the United States causing a decline in motor skills and cognition due to the destruction of dopamine producing neurons in the brain. Current research targets dopamine receptors in the brain.
Alzheimer's Phase 2 Clinical Trial Success
Neurology Diagnostics is proud to announce our participation and enrollment of patients in the Eli Lilly Alzheimer's disease study recently reported in the New York Times.